Kilitch Drugs (KILITCH)

FairStock Score: 29/100 — RISKY

Score breakdown: P/E: 1/3 · ROCE: 1/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Low leverage with debt/equity of 0.32, so the balance sheet is not heavily stressed.
• ROCE of 15.67% and ROE of 12.57% indicate reasonably efficient capital use before the recent decline.
• High promoter holding of 63.77% aligns management interest with minority shareholders.
• Price is close to book value; at P/B of 1.17, there is some asset support at ₹136.19 book value.

Concerns

• Sales declined 4.20% and net profit declined 25.67%, showing negative operating momentum.
• P/E of 21.71 is expensive for a company with falling profitability and no growth.
• Piotroski F-Score of 3/9 signals deteriorating financial health and higher risk.
• Zero dividend yield means shareholders receive no income while waiting for a turnaround.

AI Analysis

I start with a simple truth: price is what you pay, value is what you get. At ₹159.95, Kilitch Drugs trades at only 1.17 times book value, and book value is ₹136.19. So the price is not absurd relative to assets. But a business is only as good as its earnings power. The company has returned 12.57% on equity and 15.67% on capital, with a manageable debt-equity ratio of 0.32. That is fine, though not enough to make me pay a fancy multiple. The problem is the direction: sales are down 4.20%, and profits are down 25.67%. The latest quarter shows ₹54 crore in sales and only ₹4 crore in net profit. A Piotroski score of 3 out of 9 is a red flag; the financial health of the company is deteriorating. At 21.71 times earnings, the market is asking me to pay a high price for a shrinking earnings stream. There is no dividend to compensate me while I wait. Promoter holding is high at 63.77%, which is good, but high ownership alone does not create a competitive moat. If earnings keep sliding, the book value support will also weaken. I do not see a margin of safety here. Graham taught me to buy only when the facts give me both safety and an adequate return. Until I see sales and profits stabilise, and the F-score climb, I will keep Kilitch Drugs on my watchlist, not in my portfolio.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer